<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <title>Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for &quot;western patients who can afford it.” | Knowledge Ecology International</title>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="prev" href="/rn2011-1" />
<link rel="up" href="/cancer" />
<link rel="next" href="/node/1042" />
<link rel="shortcut icon" href="/sites/default/files/favicon.ico" type="image/x-icon" />
  <link type="text/css" rel="stylesheet" media="all" href="/modules/aggregator/aggregator.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/book/book.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/node/node.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/poll/poll.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/system/defaults.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/system/system.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/system/system-menus.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/user/user.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/cck/theme/content-module.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/img_assist/img_assist.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/mollom/mollom.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/og/theme/og.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/forum/forum.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/views/css/views.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/modules/print/css/printlinks.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/comment/comment.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/modules/openid/openid.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/themes/simply_modern/style.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/themes/simply_modern/css/blue.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/themes/simply_modern/css/suckerfish_blue.css?X" />
<link type="text/css" rel="stylesheet" media="all" href="/sites/all/keistyle/keistyle.css?X" />
  <script type="text/javascript" src="/misc/jquery.js?X"></script>
<script type="text/javascript" src="/misc/drupal.js?X"></script>
<script type="text/javascript" src="/sites/all/modules/img_assist/img_assist.js?X"></script>
<script type="text/javascript" src="/sites/all/modules/mollom/mollom.js?X"></script>
<script type="text/javascript" src="/sites/all/modules/og/og.js?X"></script>
<script type="text/javascript" src="/modules/openid/openid.js?X"></script>
<script type="text/javascript" src="/sites/all/themes/simply_modern/js/jquery.pngFix.js?X"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
jQuery.extend(Drupal.settings, { "basePath": "/" });
//--><!]]>
</script>
  <script type="text/javascript"> </script>
  <!--
  // this block of JS is supposed to extend the suckerfish rollovers, but it
  // seems to have no effect that I can perceive except to change the background
  // color and keep it hard encoded: not css dependant
  <script type="text/javascript">
  $(document).ready(function(){
    // Code for extending suckerfish rollovers
    $("#suckerfishmenu .content ul.menu:first > li").hover(function(event){
      $(this).children("> a").css("background",$("#footer a").css("color"));
    },function(event){
      $(this).children("> a").css("background","#3f3f3f");
    });
  });  
  </script>
  -->
      <style type="text/css">
    #page, #squeeze-top {
      width : 982px;
    }
    #top-center {
      width : 960px;
    }
    #top-container {
    padding:0;
    }
    #squeeze-top {
      background:#020202 url('/sites/all/themes/simply_modern/images/top_gradient_dark.jpg') repeat-x;
      margin:0 auto;
    }
    </style>
        <style type="text/css">
    body.sidebar-left #main {
      margin-left: -210px;
    }
    body.sidebars #main {
      margin-left: -210px;
    }
    body.sidebar-left #squeeze {
      margin-left: 210px;
    }
    body.sidebars #squeeze {
      margin-left: 210px;
    }
    #sidebar-left {
      width: 210px;
    }
    </style>
        <style type="text/css">
    body.sidebar-right #main {
      margin-right: -250px;
    }
    body.sidebars #main {
      margin-right: -250px;
    }
    body.sidebar-right #squeeze {
      margin-right: 250px;
    }
    body.sidebars #squeeze {
      margin-right: 250px;
    }
    #sidebar-right {
      width: 250px;
    }
    </style>
        <style type="text/css">
    body {
      font-family : Arial, Verdana, sans-serif;
    }
    </style>
      <!--[if lte IE 6]>
<script type="text/javascript"> 
    $(document).ready(function(){ 
        $(document).pngFix(); 
    }); 
</script> 
<![endif]-->
      <style type="text/css">
  body {
      }
  </style>
  
 
  <style type="text/css">
  #header {
            }
  </style>
<!--[if IE]>
<style type="text/css" media="all">@import "/sites/all/themes/simply_modern/css/ie.css";</style>
<![endif]-->
        <!-- <script type="text/javascript" src="http://keionline.org/sites/all/themes/simply_modern/js/pickstyle.js"></script> -->
</head>
<body class="sidebar-left">
  <div id="simplemenu_container"></div>
  <div id="simplemenu_closing-div" style="clear:both;"></div>
        <div id="top-container">
    <div id="squeeze-top">
      <div id="top-center">
        <div id="logo-title">
                            <a href="/" title="Home"> <img src="/sites/default/files/logo.png" alt="Home" id="logo" /> </a>
                      </div><!-- /logo-title -->
                      <div id="primarymenu">
                          <ul class="links primary-links"><li class="menu-613 first"><a href="https://org2.democracyinaction.org/o/5732/t/7833/shop/custom.jsp?donate_page_KEY=665" title="">Donate money to KEI</a></li>
<li class="menu-644"><a href="http://keionline.org/lists" title="">Listserves</a></li>
<li class="menu-271"><a href="/vectors" title="">Main Areas of Work</a></li>
<li class="menu-1495"><a href="http://www.youtube.com/user/KEIWashDC/videos" title="KEI youtube videos">Videos</a></li>
<li class="menu-278"><a href="/events" title="Events">Events</a></li>
<li class="menu-287"><a href="/publications" title="">Publications</a></li>
<li class="menu-227"><a href="/blog" title="">Blogs</a></li>
<li class="menu-223 last"><a href="/about" title="About KEI">About KEI</a></li>
</ul>                        <form action="/node/1910"  accept-charset="UTF-8" method="post" id="search-theme-form">
<div><div id="search" class="container-inline">
  <div class="form-item" id="edit-search-theme-form-1-wrapper">
 <label for="edit-search-theme-form-1">Search this site: </label>
 <input type="text" maxlength="128" name="search_theme_form" id="edit-search-theme-form-1" size="15" value="" title="Enter the terms you wish to search for." class="form-text" />
</div>
<input type="submit" name="op" id="edit-submit-1" value="Search"  class="form-submit" />
<input type="hidden" name="form_build_id" id="form-17b644bd28923a62ae1c980e466c2c6a" value="form-17b644bd28923a62ae1c980e466c2c6a"  />
<input type="hidden" name="form_id" id="edit-search-theme-form" value="search_theme_form"  />
</div>

</div></form>
            </div>
                </div>
      </div>
  </div>
    <div id="page" class="node-1910"><div id="shadow-right"><div id="page-bg">
      <div id="header" class="clear-block">
      <div id="name-and-slogan">
                  <h1 class='site-name'> <a href="/" title="Home"> Knowledge Ecology International </a> </h1>
                          <div class='site-slogan'> Attending and mending the knowledge ecosystem </div>
              </div><!-- /name-and-slogan -->
      
        </div><!-- /header -->
                    <div id="middlecontainer">
                        <div id="sidebar-left"><div class="block block-user" id="block-user-1">
  <h2 class="title">Navigation</h2>  <div class="content"><ul class="menu"><li class="leaf first"><a href="/sitemap" title="">Site Map</a></li>
<li class="leaf"><a href="/tracker">Recent posts</a></li>
<li class="collapsed"><a href="/aggregator">Feed aggregator</a></li>
<li class="leaf"><a href="/poll" title="">Polls</a></li>
<li class="collapsed last"><a href="/og" title="">Groups</a></li>
</ul></div></div>
<div class="block block-book" id="block-book-0">
  <h2 class="title">Book navigation</h2>  <div class="content"><div id="book-block-menu-1522" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/copyright">Copyright and Related Rights</a></li>
</ul></div>
<div id="book-block-menu-3" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/about">About KEI</a></li>
</ul></div>
<div id="book-block-menu-37" class="book-block-menu">
  <ul class="menu"><li class="expanded first last active-trail"><a href="/a2m">Access to Medical Technologies</a><ul class="menu"><li class="collapsed first"><a href="/content/view/63/1/">Collective Management of IPR and Patent Pools</a></li>
<li class="leaf"><a href="/node/395">Innovation Inducement Prizes</a></li>
<li class="collapsed"><a href="/node/1488">Legal Issues</a></li>
<li class="expanded active-trail"><a href="/node/1045">Medical diseases, conditions and technologies</a><ul class="menu"><li class="expanded first active-trail"><a href="/cancer">Cancer</a><ul class="menu"><li class="leaf first"><a href="/rn2011-1">Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list</a></li>
<li class="leaf active-trail"><a href="/node/1910" class="active">Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for &quot;western patients who can afford it.”</a></li>
<li class="leaf"><a href="/node/1042">CDC estimates of the ratio of deaths to new cases of breast cancer in the United States, 1975 to 2007</a></li>
<li class="leaf"><a href="/node/1041">Cancer health disparities in the United States</a></li>
<li class="leaf"><a href="/node/1039">Cancer: Annual deaths compared to new cases  in 2004, for 16 types of cancer and 4 World Bank income groups</a></li>
<li class="leaf"><a href="/node/1044">Differences in deaths for 6 cancer types in 14 WHO regions, with reference to income of region</a></li>
<li class="leaf"><a href="/node/1640">IPAB hearing on the Nexavar compulsory license, part 1, R&amp;D costs</a></li>
<li class="leaf"><a href="/node/1384">KEI Statement on India&#039;s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)</a></li>
<li class="leaf"><a href="/node/1657">KEI&#039;s February 17, 2013 Statement in Nexavar India compulsory licensing case</a></li>
<li class="leaf"><a href="/node/1031">NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)</a></li>
<li class="collapsed"><a href="/node/1446">Nexavar compulsory license case in India</a></li>
<li class="leaf"><a href="/node/114">Propuesta: Pools de Patentes para el Cancer</a></li>
<li class="leaf"><a href="/node/1038">Ratio of year 2000 breast cancer deaths to new breast cancer patients in Europe, by country and country income</a></li>
<li class="leaf"><a href="/node/1358">Sorafenib (Nexavar)</a></li>
<li class="leaf"><a href="/node/85">The Gotham Prize</a></li>
<li class="leaf"><a href="/node/1680">Top WIPO PCT applicants for patents with cancer in specification or description</a></li>
<li class="leaf last"><a href="/node/1924">Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar</a></li>
</ul></li>
<li class="leaf"><a href="/node/1046">Disparities in Asthma Outcomes in 2004</a></li>
<li class="leaf"><a href="/drugs">Drugs</a></li>
<li class="leaf last"><a href="/node/1047">Tuberculosis outcomes by WHO region and income in 2004</a></li>
</ul></li>
<li class="collapsed"><a href="/node/398">TRIPS Flexibilities and Compulsory Licensing</a></li>
<li class="collapsed"><a href="/testdata">Test data protection for medical inventions</a></li>
<li class="collapsed last"><a href="/whoiplusa">WHO Negotiations on Public Health, Innovation and Intellectual Property</a></li>
</ul></li>
</ul></div>
<div id="book-block-menu-1880" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/Companies">Companies</a></li>
</ul></div>
<div id="book-block-menu-657" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/competition">Competition Policy</a></li>
</ul></div>
<div id="book-block-menu-1311" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/data">Databases</a></li>
</ul></div>
<div id="book-block-menu-36" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/economics">Economics of Creativity and Knowledge</a></li>
</ul></div>
<div id="book-block-menu-399" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/enforcement">Enforcement and Remedies to Infringement</a></li>
</ul></div>
<div id="book-block-menu-25" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/events">Events</a></li>
</ul></div>
<div id="book-block-menu-24" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/a2k">General Access to Knowledge Issues</a></li>
</ul></div>
<div id="book-block-menu-972" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/node/972">Government Funded Inventions</a></li>
</ul></div>
<div id="book-block-menu-614" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/fora">Knowledge Governance Fora</a></li>
</ul></div>
<div id="book-block-menu-656" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/nuclear">Nuclear Proliferation</a></li>
</ul></div>
<div id="book-block-menu-585" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/patents">Patent Policy</a></li>
</ul></div>
<div id="book-block-menu-23" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/prizes">Prizes to stimulate innovation</a></li>
</ul></div>
<div id="book-block-menu-32" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/publications">Publications and Research Notes</a></li>
</ul></div>
<div id="book-block-menu-944" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/timelines">Timelines</a></li>
</ul></div>
<div id="book-block-menu-20" class="book-block-menu">
  <ul class="menu"><li class="collapsed first last"><a href="/transparency">Transparency</a></li>
</ul></div>
</div></div>
<div class="block block-user" id="block-user-0">
  <h2 class="title">User login</h2>  <div class="content"><form action="/node/1910?destination=node%2F1910"  accept-charset="UTF-8" method="post" id="user-login-form">
<div><div class="form-item" id="edit-openid-identifier-wrapper">
 <label for="edit-openid-identifier">Log in using OpenID: </label>
 <input type="text" maxlength="255" name="openid_identifier" id="edit-openid-identifier" size="13" value="" class="form-text" />
 <div class="description"><a href="http://openid.net/">What is OpenID?</a></div>
</div>
<div class="form-item" id="edit-name-wrapper">
 <label for="edit-name">Username: <span class="form-required" title="This field is required.">*</span></label>
 <input type="text" maxlength="60" name="name" id="edit-name" size="15" value="" class="form-text required" />
</div>
<div class="form-item" id="edit-pass-wrapper">
 <label for="edit-pass">Password: <span class="form-required" title="This field is required.">*</span></label>
 <input type="password" name="pass" id="edit-pass"  maxlength="60"  size="15"  class="form-text required" />
</div>
<input type="submit" name="op" id="edit-submit" value="Log in"  class="form-submit" />
<input type="hidden" name="form_build_id" id="form-e9c698401097451ea864a291e60e5039" value="form-e9c698401097451ea864a291e60e5039"  />
<input type="hidden" name="form_id" id="edit-user-login-block" value="user_login_block"  />
<input type="hidden" name="openid.return_to" id="edit-openid.return-to" value="http://keionline.org/openid/authenticate?destination=node%2F1910"  />
<div class="item-list"><ul><li class="openid-link first"><a href="/%2523">Log in using OpenID</a></li>
<li class="user-link last"><a href="/%2523">Cancel OpenID login</a></li>
</ul></div><div class="item-list"><ul><li class="first last"><a href="/user/password" title="Request new password via e-mail.">Request new password</a></li>
</ul></div>
</div></form>
</div></div>
 </div>
                          <div id="main">
        <div id="squeeze">
                                    <div id="breadcrumb"> <div class="breadcrumb"><a href="/">Home</a> » <a href="/blog">Blogs</a> » <a href="/blog/jamie">James Love&#039;s blog</a></div> </div>
                                          <div id="squeeze-content">
                        <div id="inner-content"  class="node-1910" >
                           <h1 class="title">Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for &quot;western patients who can afford it.”</h1>
              <div class="tabs"><ul class="tabs primary">
<li class="active" ><a href="/node/1910" class="active">View</a></li>
<li ><a href="/node/1910/backlinks">What links here</a></li>
</ul>
</div>
                                          <div class="node">
  
        <span class="submitted">Submitted by James Love on 22. January 2014 - 13:05</span> 
    
  <div class="content"><table align="right" hspace="10" width="200">
<tr>
<td><img src="/sites/default/files/u4/dr-dekkers_280_en.jpg" width="200" height="" alt="dr-dekkers_280_en.jpg" /></td>
</tr>
<tr>
<td>Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.”</td>
</tr>
</table>
<p>[<strong>UPDATE: The <a href="http://keionline.org/node/1924">latest blog and transcript</a> of Bayer CEO Marijn Dekkers' full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.</strong>]</p>
<p>Today health advocates were shocked by the direct and appalling statements attributed to Bayer CEO Marijn Dekkers.  Published in Businessweek on January 21, 2014 and written by Bloomberg reporter Ketaki Gokhale, a news story about disputes over drug patents (link <a href="http://www.businessweek.com/news/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-drug-patents">here</a>) ended with an account of the India compulsory license on the cancer drug Nexavar, and practically exploded.   Dekker is quoted as saying Bayer did not intend the cancer drug to be sold to cancer patients in India, adding “We developed it for western patients who can afford it.”  From the Bloomberg/Businessweek story:</p>
<blockquote><p>Under India’s patent laws, compulsory licenses can be awarded for some products still under patent if the original isn’t available locally at a reasonable price.</p>
<p>Natco Pharma Ltd. (NTCPH) applied directly to India’s patents office and was awarded the nation’s first compulsory license in March 2012 to make a copy of Bayer’s Nexavar cancer drug at a 97 percent discount to the original product. In March last year, Bayer lost its bid to stop Natco from making the generic drug and is appealing the decision at the Mumbai High Court.</p>
<p>Bayer Chief Executive Officer Marijn Dekkers called the compulsory license “essentially theft.”</p>
<p>“We did not develop this medicine for Indians,” Dekkers said Dec. 3. “We developed it for western patients who can afford it.”</p></blockquote>
<p>Apparently the December 3, 2013 quote is from an earlier largely overlooked event hosted by the FT.  For more context, note that the Bayer price for Nexavar was $65 thousand USD, per year, in India, and that Bayer is currently arguing that the $65 thousand price is "reasonably affordable" to the India Supreme Court.  Dekker's comments will likely be quoted extensively in India, and I would not be surprised to see them quoted in a decision rejecting the Bayer appeal.   It is worth noting that <a href="http://www.bayer.com/en/dr.-marijn-dekkers.aspx">Dekkers</a>, who holds  both Dutch and U.S. citizenship, is a member of the Board of Directors of General Electric, another company that takes a very hard line on intellectual property issues.  (See, for example: <a href="http://keionline.org/node/1822" title="http://keionline.org/node/1822">http://keionline.org/node/1822</a>). </p>
<p>The U.S. government has weighed in on the side of Bayer in the patent case, at the highest levels of the India and the US governments.   For more on background on the Nexavar case, see: KEI's February 17, 2013 Statement in Nexavar India compulsory licensing case.  <a href="http://keionline.org/node/1657">http://keionline.org/node/1657</a></p>
<p>And: <a href="http://keionline.org/search/node/nexavar">http://keionline.org/search/node/nexavar</a></p>
<p>Video of the December 3, 2013 event where Marjin Dekker made the statement in question; Financial Times Live, "Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust-PANEL." <a href="https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel">https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel</a></p>
<hr />
<p>There is also a January 23, 2014 MSF response to Bayer CEO statement that its medicines are developed only for western patients.  (Link <a href="http://www.msfaccess.org/content/msf-response-bayer-ceo-statement-medicines-developed-only-western-patients">here</a>).</p>
<p><strong>Additional commentary</strong></p>
<p>John LaMattina, the former president of R&amp;D for Pfizer, wrote about the Dekkers/Bayer quote in a Forbes Blog on December 5, 2014. (Link <a href="http://www.forbes.com/sites/johnlamattina/2013/12/05/does-pharma-only-develop-drugs-for-those-who-can-pay/">here</a>). If you read the comments, there is a response from Marijn Dekkers, as Chairman of the Board of Management of Bayer AG.   (Dekkers is both the CEO and the Chairman of the Board of Management).</p>
<p>Chittum, Ryan. "Bloomberg's Viral Misquote." Columbia Journalism Review. 29 January 2014. <a href="http://www.cjr.org/the_audit/bloombergs_viral_misquote_1.php">http://www.cjr.org/the_audit/bloombergs_viral_misquote_1.php</a></p>
<p>Updated article in Bloomberg, "Merck to Bristol-Myers Face More Threats on India Patents," by Ketaki Gokhale. 28 January 2014. <a href="http://www.bloomberg.com/news/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-patents.html">http://www.bloomberg.com/news/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-patents.html</a></p>
<p>Grogan, Kevin. "Patients do not appreciate life-saving pharma: Bayer chief." PharmaTimes.com 04 December 2013. <a href="https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel">https://www.ft-live.com/ft-events/ft-global-pharmaceuticals-biotechnology-conference-2013/sessions/buffering-the-pharma-brand-restoring-reputation-rebuilding-trust-panel</a></p>
<p>Daily Mail. "'We didn't make this medicine for Indians… we made it for western patients who can afford it': Pharmaceutical chief tries to stop India replicating its cancer treatment." 24 January 2014.  <a href="http://www.dailymail.co.uk/news/article-2545360/Pharmaceutical-chief-tries-stop-India-replicating-cancer-treatment.html">http://www.dailymail.co.uk/news/article-2545360/Pharmaceutical-chief-tries-stop-India-replicating-cancer-treatment.html</a></p>
<p>Peck, Adam. "Pharmaceutical CEO: Cancer Drug is Only for Westerners Who Can Afford It." ThinkProgress. 26 January 2014. <a href="http://thinkprogress.org/health/2014/01/26/3205861/pharmaceutical-ceo-cancer-drug-westerners-afford/">http://thinkprogress.org/health/2014/01/26/3205861/pharmaceutical-ceo-cancer-drug-westerners-afford/</a></p>
<p>Allen, Michael. "Bayer CEO Says New Cancer Drug Wasn't Made For Indians, Only Westerners." OpposingViews.com. 26 January 2014. <a href="http://www.opposingviews.com/i/health/conditions/cancer/bayer-ceo-says-new-cancer-drug-wasnt-made-indians-only-westerners">http://www.opposingviews.com/i/health/conditions/cancer/bayer-ceo-says-new-cancer-drug-wasnt-made-indians-only-westerners</a></p>
<p>Dawn, April. "Big Pharma CEO: Cancer Drug is Only for Westerners Who Can Afford It." TheSource.com. 26 January 2014. <a href="http://thesource.com/2014/01/26/big-pharma-ceo-cancer-drug-is-only-for-westerners-who-can-afford-it/">http://thesource.com/2014/01/26/big-pharma-ceo-cancer-drug-is-only-for-westerners-who-can-afford-it/</a></p>
<p>Agence France-Presse. "MSF slams Bayer for saying drugs for those who can pay." GlobalPost.com. 24 January 2014. <a href="http://www.globalpost.com/dispatch/news/afp/140124/msf-slams-bayer-saying-drugs-those-who-can-pay">http://www.globalpost.com/dispatch/news/afp/140124/msf-slams-bayer-saying-drugs-those-who-can-pay</a></p>
  <div id="book-navigation-37" class="book-navigation">
    
        <div class="page-links clear-block">
              <a href="/rn2011-1" class="page-previous" title="Go to previous page">‹ Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list</a>
                    <a href="/cancer" class="page-up" title="Go to parent page">up</a>
                    <a href="/node/1042" class="page-next" title="Go to next page">CDC estimates of the ratio of deaths to new cases of breast cancer in the United States, 1975 to 2007 ›</a>
          </div>
    
  </div>
</div>
  <div class="clear-block clear"></div>

      <div class="links"><ul class="links inline"><li class="blog_usernames_blog first"><a href="/blog/jamie" title="Read James Love&#039;s latest blog entries.">James Love&#039;s blog</a></li>
<li class="book_printer"><a href="/print/book/export/html/1910" title="Display a printer-friendly version of this page." class="print-page" onclick="window.open(this.href); return false" rel="nofollow">Printer-friendly version</a></li>
<li class="comment_add"><a href="/comment/reply/1910#comment-form" title="Share your thoughts and opinions related to this posting.">Add new comment</a></li>
<li class="book_mail last"><a href="/printmail/book/export/html/1910" title="Send this page by email." class="print-mail" rel="nofollow">Send by email</a></li>
</ul></div>
  
</div>
 
                                        </div><!-- /inner-content -->
          </div><!-- /squeeze-content -->
        </div><!-- /squeeze -->
      </div><!-- /main -->
                              </div><!-- /middle-container -->
    <div style="clear:both"></div>
                  <div id="secondary-links">
         
        <div style="clear:both"></div>
      </div>
        <div id="footer">
              <div id="footer-region"><div class="block block-block" id="block-block-7">
    <div class="content"><p><a href="https://org2.democracyinaction.org/o/5732/t/4251/shop/custom.jsp?donate_page_KEY=665">Support KEI</a></p>
</div></div>
</div>
                    <div id="footer-message">WASHINGTON 1621 Connecticut Ave. NW, Suite 500, Washington, DC 20009 /TEL: +1.202.332.2670 · FAX +1.202.332.2673   GENEVE 1 Route des Morillons, CP 2100, 1211 Genève 2, Switzerland TEL: +41.22.791.6727</div>
          <div style="color:gray"><strong>THEME DESIGN</strong> Copyright &#169; 2009 under <a href="http://www.gnu.org/licenses/gpl.html" target="_blank">GPL</a> by <a href="http://www.tributemedia.com" title="High Performing, Industry Specific Websites" target="_blank">Tribute Media</a>. Site Powered by <a href="http://drupal.org/">Drupal</a>.</div>
    </div><!-- /footer -->
  <div style="clear:both"></div>
  </div></div>
  </div> <!-- /page -->
</body>
</html>